← Eichor
Condition: Myxoid Liposarcoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myxoid Liposarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Phase 1/Phase 2 · 17 location(s) · Grupo Espanol de Investigacion en Sarcomas · NCT02275286NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C
EARLY_Phase 1 · 1 location(s) · Seth Pollack · NCT07261657START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Phase 1 · 7 location(s) · Valo Therapeutics Oy · NCT05492682International Prospective Registry on Local Treatment Approaches in MLS
Phase N/A · 1 location(s) · The Netherlands Cancer Institute · NCT04699292A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Phase 1/Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06843967Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06083883First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Phase 1 · 7 location(s) · Daiichi Sankyo · NCT06644755
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.